QTS Stock Overview Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
IQVIA Holdings Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for IQVIA Holdings Historical stock prices Current Share Price US$189.85 52 Week High US$238.00 52 Week Low US$177.35 Beta 1.48 1 Month Change -1.45% 3 Month Change -9.08% 1 Year Change -5.55% 3 Year Change -15.58% 5 Year Change 31.84% Change since IPO 432.75%
Recent News & Updates
IQVIA Holdings Inc. Updates Earnings Guidance for the Full Year 2024 Nov 01
Third quarter 2024 earnings released: EPS: US$1.57 (vs US$1.66 in 3Q 2023) Nov 01
IQVIA Holdings Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 16
Second quarter 2024 earnings released: EPS: US$1.99 (vs US$1.61 in 2Q 2023) Jul 23
IQVIA Holdings Inc. Updates Earnings Guidance for the Full Year 2024 Jul 22
IQVIA Holdings Inc. to Report Q2, 2024 Results on Jul 22, 2024 Jul 09 See more updates
IQVIA Holdings Inc. Updates Earnings Guidance for the Full Year 2024 Nov 01
Third quarter 2024 earnings released: EPS: US$1.57 (vs US$1.66 in 3Q 2023) Nov 01
IQVIA Holdings Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 16
Second quarter 2024 earnings released: EPS: US$1.99 (vs US$1.61 in 2Q 2023) Jul 23
IQVIA Holdings Inc. Updates Earnings Guidance for the Full Year 2024 Jul 22
IQVIA Holdings Inc. to Report Q2, 2024 Results on Jul 22, 2024 Jul 09
IQVIA Launches “One Home” Clinical Trial Technology Platform, Solves Challenges and Reduces Overload at Sitestes Jun 15
Iqvia Holdings Inc. Announces Transition of Kevin C. Knightly, President, Corporate Strategy and Enterprise Networks to Become A Senior Advisor to the Chief Executive Officer, Effective May 15, 2024 May 11
First quarter 2024 earnings released: EPS: US$1.58 (vs US$1.56 in 1Q 2023) May 02
IQVIA Holdings Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 16
Insider recently sold €3.2m worth of stock Mar 07
IQVIA Holdings Inc., Annual General Meeting, Apr 16, 2024 Feb 24
Insider recently sold €1.2m worth of stock Feb 23
Full year 2023 earnings released: EPS: US$7.39 (vs US$5.82 in FY 2022) Feb 15
IQVIA Holdings Inc. Provides Earnings Guidance for the Full Year of 2024 Feb 14
IQVIA Holdings Inc. to Report Q4, 2023 Results on Feb 14, 2024 Jan 25
IQVIA Holdings Inc. Provides Financial Guidance for the Fourth Quarter and Full-Year of 2023 Nov 02
Third quarter 2023 earnings released: EPS: US$1.66 (vs US$1.52 in 3Q 2022) Nov 02 IQVIA Holdings Inc. to Report Q3, 2023 Results on Nov 01, 2023
IQVIA Holdings Inc. Appoints Richard Staub III President of Research & Development Solutions Sep 26
Insider recently sold €3.9m worth of stock Sep 23
IQVIA Holdings Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023 Aug 02
Second quarter 2023 earnings released: EPS: US$1.61 (vs US$1.36 in 2Q 2022) Aug 02
IQVIA Holdings Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 07
IQVIA Launches RIM Smart Labeling to Deliver Intelligence-Driven Approach for Global Label Management Jun 28
Insider recently sold €1.1m worth of stock Jun 11
First quarter 2023 earnings released: EPS: US$1.56 (vs US$1.71 in 1Q 2022) Apr 28
Insider recently sold €940k worth of stock Feb 19
Full year 2022 earnings released: EPS: US$5.82 (vs US$5.05 in FY 2021) Feb 12
IQVIA Holdings Inc. Provides Revenue Guidance for the Fiscal Year 2023 Feb 11
IQVIA Holdings Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023 Jan 26
Third quarter 2022 earnings released: EPS: US$1.52 (vs US$1.36 in 3Q 2021) Oct 27 IQVIA Holdings Inc. Provides Earnings Guidance for the Fourth Quarter of 2022 Iqvia Holdings Inc. Announces Resignation of Ronald A. Rittenmeyer as Member of the Board of Directors and Chairman of the Leadership Development and Compensation Committee
IQVIA Announces its Decentralized Clinical Trial (DCT) Program Receives GDPR Compliance Validation from TRUSTArc Sep 29
IQVIA Holdings Inc. Announces New Evidence That Decentralized Clinical Trials (DCT) Deliver Measurable Benefits for Patients, Sites and Sponsors Sep 08
GSK plc and IQVIA launch Vaccine Track Aug 09
IQVIA Holdings Inc. Announces Executive Changes Jul 30
Second quarter 2022 earnings released: EPS: US$1.36 (vs US$0.91 in 2Q 2021) Jul 22
IQVIA Holdings Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2022 Jul 22
IQVIA Holdings Inc. to Report Q2, 2022 Results on Jul 21, 2022 Jul 08
IQVIA Appoints Christina Mack as Chief Scientific Officer of Real World Solutions, Effective from July 7, 2022 Jun 08
First quarter 2022 earnings released: EPS: US$1.71 (vs US$1.11 in 1Q 2021) Apr 28
IQVIA Holdings Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2022 Apr 28
IQVIA Holdings Inc. to Report Q1, 2022 Results on Apr 27, 2022 Apr 13
IQVIA Holdings Inc. Selects to Support EMA’S DARWIN EU Coordination Centre Initiative Mar 31
IQVIA Holdings Inc., Annual General Meeting, Apr 12, 2022 Mar 01
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 16
IQVIA Holdings Inc. Provides Financial Guidance for the First Quarter and Full Year 2022 Feb 16
IQVIA Holdings Inc. to Report Q4, 2021 Results on Feb 15, 2022 Feb 02
Independent Director recently bought €2.4m worth of stock Dec 25
IQVIA Decentralized Trial Suite Launches Mobile Research Nursing and Phlebotomy Services Unit Dec 03
Third quarter 2021 earnings released: EPS US$1.36 (vs US$0.53 in 3Q 2020) Oct 23
IQVIA Launches New A.I.-Powered MI Contact Center for Life Sciences Sep 02
Insufficient new directors Aug 02
Second quarter 2021 earnings released: EPS US$0.91 (vs US$0.12 loss in 2Q 2020) Jul 28
IQVIA Launches the Clinical Data Analytics Suite to Enable Smarter, Faster Clinical Trials Jun 25
IQVIA Announces That Mischaracterizes Nature of Recent Procedural E-Discovery Ruling in Veeva Systems Antitrust Case Against IQVIA May 12
Iqvia Announces Connected Intelligence Apr 29 IQVIA Holdings Inc. Provides Earnings Guidance for the Second Quarter of 2021
IQVIA Collaborates with Janssen Research & Development on Their Investigational Covid-19 Vaccine Trials Mar 10
IQVIA Holdings Inc., Annual General Meeting, Apr 13, 2021 Feb 27
New 90-day high: €158 Feb 12
Full year 2020 earnings released: EPS US$1.46 (vs US$0.98 in FY 2019) Feb 11
Revenue beats expectations Feb 11
IQVIA Holdings Inc. Raises Earnings Guidance for the Full Year of 2021 Feb 11
IQVIA Holdings Inc. to Report Q4, 2020 Results on Feb 10, 2021 Jan 27
New 90-day high: €151 Jan 07
Laboratoires Théa Selects Iqvia Oce and Onekey to Accelerate Its Global Digital Transformation Jan 06
Independent Director recently bought €9.2m worth of stock Dec 29
IQVIA and Servier Collaborate to Reinvent Clinical Development Dec 18
Independent Director recently sold €6.0m worth of stock Nov 20
New 90-day high: €150 Nov 10
IQVIA’s Orchestrated Customer Engagement Platform Selected by Zentiva to Accelerate Digital Capabilities Nov 03
Third quarter earnings released Oct 21
Third-quarter earnings released: Revenue beats expectations Oct 21
IQVIA Joins U.S. Food and Drug Administration to Advance COVID-19 Understanding at Community Level through COVID Active Research Experience (CARE) Project Oct 13
New 90-day high: €144 Oct 12
IQVIA Holdings Inc. to Report Q3, 2020 Results on Oct 20, 2020 Oct 08
New 90-day high - €142 Sep 03
New 90-day high - €137 Jul 21
IQVIA Holdings Inc. to Report Q2, 2020 Results on Jul 22, 2020 Jul 09 Shareholder Returns QTS DE Life Sciences DE Market 7D -0.6% 0.2% 0.7% 1Y -5.5% -2.4% 8.4%
See full shareholder returns
Return vs Market: QTS underperformed the German Market which returned 8.4% over the past year.
Price Volatility Is QTS's price volatile compared to industry and market? QTS volatility QTS Average Weekly Movement 4.5% Life Sciences Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: QTS has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: QTS's weekly volatility (5%) has been stable over the past year.
About the Company IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Show more IQVIA Holdings Inc. Fundamentals Summary How do IQVIA Holdings's earnings and revenue compare to its market cap? QTS fundamental statistics Market cap €34.48b Earnings (TTM ) €1.37b Revenue (TTM ) €14.91b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) QTS income statement (TTM ) Revenue US$15.32b Cost of Revenue US$9.93b Gross Profit US$5.39b Other Expenses US$3.98b Earnings US$1.41b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 7.74 Gross Margin 35.17% Net Profit Margin 9.17% Debt/Equity Ratio 194.9%
How did QTS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/03 08:22 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources IQVIA Holdings Inc. is covered by 44 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jasper Hellweg Argus Research Company Gregory Bolan Avondale Partners Eric Coldwell Baird
Show 41 more analysts 
